Sniffles & Arthritis (3.1.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Are these associations with infection, biomarkers and weather real or imaginary? Linked or luck? Causal or casual? You decide....
Immunosuppression Increasing (2.23.2024)
Dr. Jack Cush reviews the news and journal reports from the past 2 weeks on RheumNow.com; but begins with a discussion of what constitutes "immunosuppression" and how it applies to our patients.
Autoimmune disease and pregnancy
EurekAlert!
For many aspiring mothers with autoimmune disease, pregnancy can be daunting and full of unknowns. In some cases, those suffering from specific autoimmune conditions have chosen to forego pregnancy altogether due to concerns about their disease treatments and adverse pregnancy outcomes.
Dead Words Eulogy
Editor's note: This is a bonus lecture provided to RheumNow Live 2024 registrants, and being shared with our RheumNow audience. Today is the last day to register to attend virtually (or in person); go to https://rheumnow.live/ for more information.
2023 Rheumatology Year in Review
Dr. Jack Cush reviews highlights, advances and hot topics in rheumatology from 2023 and the RheumNow website.
2023 was a year of growth and new horizons while returning to operational and practice standards (in care and education) established before the pandemic.
Drug-Induced Dermatomyositis
A JAMA Dermatology systematic review of drug-induced dermatomyositis (DM) found the most commonly implicated agents include hydroxyurea, immune checkpoint inhibitors, statins and lipid-lowering agents, penicillamine, and tumor necrosis factor inhibitors.
Heritability of Osteoarthritis
A Swedish study examine the genetic contribution to various rheumatic/musculoskeletal diseases (RMDs) and showed that osteoarthritis (OA) had a large heritability compared with other RMDs.
New Year's Resolutions (1.5.2024)
Dr. Jack Cush imparts his new New Year's Resolutions for 2024 and also reviews the news and journal reports from the past week on RheumNow.com.
Best of 2023: Cost-Effective Use of Biological and Targeted Synthetic DMARDs
Editor's note: this article originally appeared March 14, 2023, and is being shared again as a Best of 2023. Enjoy!
Best of 2023: 25 Great Women in Rheumatology
Editor's note: this article originally appeared April 26, 2023, and is being shared again as a Best of 2023. Enjoy!
ICYMI: ACR Plenaries: Changing the Practice of Rheumatology
The Merriam-Webster definitions of “plenary” include: 1. complete in every respect: absolute, unqualified and 2. fully attended or constituted by all entitled to be present.
Social
17S19 session on steroid free future
@LesleyJacksonMD @EBRheum @BritAdlerMD
Is a (near) steroid free future for RA, ANCA, Lupus
#ACR24 @RheumNow
Eric Dein @ericdeinmd ( View Tweet )
10 months ago
If high +ANA and NO #rheumatic #disease LOOK 👀 at #LIVER #Autoimmune #hepatitis And #alcoholic #liver #dx #ACRBest #ACR24 @rheumnow abst#0627 https://t.co/EVLUyvpBfD
Links:
Janet Pope @Janetbirdope ( View Tweet )
10 months ago
The future use of a panel of immunological urinary biomarkers as a liquid biopsy for the management of lupus nephritis. Plenary Abstr#1642 @RheumNow #ACR24 https://t.co/waSRVd7FV7
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
10 months ago
Dr @andreafava presents their noninvasive biomarker panel that predicted the probability of histologically active LN.
Panel outperformed UPCR, C3, C4 & antidsDNA.
Aid in clinical-decision making? Lots of potential for monitoring tx response.
@Rheumnow #ACR24 abs1642
#ACRbest https://t.co/C7ZNdvbIQ7
Links:
sheila @RHEUMarampa ( View Tweet )
10 months ago
Impressive Plenary @andreafava just finished Novel urine protein panel id 12 proteins that predict NIH activity on renal bx better than existing options Improving at 3 mos predicts response at 1 year Could reduce biopsies / modulate tx! #ACR24 @RheumNow Abstr#1642 #ACRbest https://t.co/Gi6u6hAGzj
Links:
Mike Putman @EBRheum ( View Tweet )
10 months ago
Interim analysis of a Phase 4 study of ARD (RA 25%, SLE 25%) patients shows recombinant herpes zoster vaccine(RZV) good safety profile, with no impact on disease activity (flare rates: 13.6% vs. 12.4%). Immunogenicity: 93% response in ARDs vs. 99% in controls. Rituximab & MMF… https://t.co/U3s48fLduX https://t.co/WTvD5shtXB
Links:
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
10 months ago
This poster makes me happy for so many reasons 😆
Aggressive & descriptive title? ☑️
Pretty chloropleth map? ☑️
Dunks on hamfisted EMR tools trying to replace patient-physician interactions? ☑️
@RheumNow #ACR24 Abstr#0668 ThereAreNoShortcuts https://t.co/IXYaHAi15q
Mike Putman @EBRheum ( View Tweet )
10 months ago
This is likely an oversimplification, but I've been looking for exactly this diagram
Inhibiting various TYKs/JAKs corresponds to various downstream cytokine inhibition
@EricFMorand does it make sense to see this as anifrolumab+ustekinumab? No?
@rheumnow #ACR24 Abstr#0662 https://t.co/thti6s5TR3
Links:
Mike Putman @EBRheum ( View Tweet )
10 months ago
Cardiology 🤝 Rheumatology
#Abstract0611 highlights Subclinical atherosclerosis (carotid plaque > 1.5 mm) associated with ↑ risk of CV events in SLE longitudinal cohort
@RheumNow #ACR24 https://t.co/jLLYNOfFZ2
Akhil Sood MD @AkhilSoodMD ( View Tweet )
10 months ago
Which lupus nephritis patients are at higher risk for CKD? #Abstract0624 shows coexisting tubulointerstitial inflammation/damage (TII/TID) on renal biopsy is linked to CKD progression (HR 2.667, 95% CI: 1.333-5.335)
Risk high among Class III, IV, V and eGFR > 30
@RheumNow #ACR24
Akhil Sood MD @AkhilSoodMD ( View Tweet )
10 months ago
